Visual function more than 10 years after @entity7995 : experience of the XXXX treatment trial.

@entity1 @entity15 @entity7995
PURPOSE: To assess visual function more than 10 years after an episode of @entity7995 in @entity1 enrolled in the @entity7995 Treatment Trial. DESIGN: Longitudinal follow-up of a randomized clinical trial. METHODS: Vision testing included measures of visual acuity, contrast sensitivity, and visual field. Quality of life was assessed with the National Eye Institute Visual Function Questionnaire. RESULTS: Examinations were completed on 319 @entity1 . In most @entity1 , visual function test results in the eyes that experienced @entity7995 at study entry ("affected eyes") were normal or only slightly abnormal after 9.9 to 13.7 years. Visual acuity in the affected eyes was >or=20/20 in 74%, 20/25 to 20/40 in 18%, <20/40 to 20/200 in 5%, and <20/200 in 3%. On average, visual function was worse in @entity1 with @entity15 ( @entity15 ) than in those without @entity15 . Recurrent @entity7995 in either eye occurred in 35% of @entity1 . Such attacks were more frequent in @entity1 with @entity15 (P <.001). The National Eye Institute Visual Function Questionnaire scores were lower when visual acuity was abnormal and when @entity15 was present. CONCLUSIONS: Most @entity1 retained good to excellent vision more than 10 years after an attack of @entity7995 . Recurrences were more frequent in @entity1 with @entity15 .
